Dataset Information


TBCRC003: Phase II Study of Trastuzumab & Lapatinib in Metastatic HER + Breast Cancer

ABSTRACT: Although several large-scale breast cancer sequencing studies have elucidated the spectrum of genomic alterations in primary, treatment-naive breast tumors, the genomic landscape of metastatic HER2+ breast cancer remains under explored. Furthermore, tumor genomic alterations that arise after progression on anti-HER2 therapy remain largely unknown. To explore these two questions, we prospectively collected metastatic tumor biopsies from patients enrolled on TBCRC003 (NCT00470704), a phase II study evaluating the combination of lapatinib and trastuzumab in patients with metastatic HER2+ breast cancer. By design, patients had varying degrees of prior trastuzumab exposure in the metastatic setting (0-2 prior lines). A baseline tumor biopsy was required at time of study entry. We carried out whole exome sequencing of metastatic frozen tumors and matched normal. We were also able to obtain and sequence the matched archival FFPE primary tumors for most of the... (for more see dbGaP study page.)

PROVIDER: phs000943 | dbGaP |



Similar Datasets

1000-01-01 | S-EPMC3663661 | BioStudies
2019-01-01 | S-EPMC6513990 | BioStudies
2012-01-01 | S-EPMC3525734 | BioStudies
2019-01-01 | S-EPMC6927318 | BioStudies
2019-01-01 | S-EPMC6872692 | BioStudies
2012-01-01 | S-EPMC3287235 | BioStudies
2014-01-01 | S-EPMC3977457 | BioStudies
2019-01-01 | S-EPMC6626398 | BioStudies
2018-01-01 | S-EPMC6498841 | BioStudies
2020-01-01 | S-EPMC7281325 | BioStudies